Challenges To Making Go/No-Go Decisions In Clinical Trials

In drug development, a go/no-go decision can be a high-stakes trade-off between speed and certainty. Move too slow, and competitors can seize the market before you arrive. Move too fast on poor-quality data, and you risk progressing a non-viable therapeutic or killing a promising one.

In this candid panel discussion, former Genentech/Roche Global SVP Nancy Valente joins seasoned drug developer and TruTechnologies Co-Founder Richard Graham to discuss the real-world operational and strategic hurdles to making data-driven go/no-go decisions.

The conversation covers:

• Why data quality remains the common denominator in go/no-go decisions across development
• How slow data delivery, missing information, and noisy data can cloud study interpretation
• How predefined decision criteria and organizational alignment help teams navigate gray-area results
• How investor expectations, competitive timelines, and funding realities shape the decision environment